The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive data generated in exosome collaboration

11 Oct 2021 07:00

RNS Number : 5689O
ReNeuron Group plc
11 October 2021
 

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Positive data generated in exosome programme collaboration

 

Significantly improved delivery of functional proteins to the brain demonstrated in vivo

Exosomes have potential to transform effective drug delivery for key neurological diseases

 

ReNeuron Group plc (AIM: RENE), a global leader in the development of exosome therapeutics, announces positive data that provides clear pre-clinical proof-of-concept that ReNeuron's novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

 

In an ongoing collaboration with scientists at the University of Salamanca, Spain, ReNeuron has sought to determine whether its stem cell-derived exosomes can deliver a therapeutic protein to the corpus striatum; a region of the brain affected by disabling neurological diseases such as stroke, Parkinson's Disease and Huntington's disease.

 

Major pharmaceutical companies have identified therapeutic proteins that are effective in treating a variety of neurological diseases. However, there are major issues associated with the delivery of these protein therapeutics, which include the poor stability in living organisms, given that proteins rapidly break down and do not last long in the body; as well as issues surrounding poor tissue distribution due to an inability to target specific tissues. Whilst these issues cannot be overcome by simply administering more protein, as this can have unwanted side-effects, ReNeuron believes that its proprietary exosomes have the potential to address both these issues due to their natural tissue-targeting ability and superior stability characteristics.

 

Studies performed in collaboration with the University of Salamanca established that exosomes administered intrathecally were capable of delivering a therapeutic protein in an animal model (in vivo) to regions of the brain at a functional activity level much greater than that seen when simply supplying the protein alone. Contrary to this, studies performed in the laboratory showed no difference in delivery between the exosomal based protein and the protein alone. This difference between the efficiency of in vivo delivery versus in vitro delivery suggests that the exosome linked proteins were able to overcome the obstacle of protein breakdown and tissue targeting in the brain that was not possible with the native protein. The in vivo results are key in showing that ReNeuron's exosome delivery technology offer a striking higher stability, more targeted delivery, and an increase in potency, therefore potentially solving the delivery issues that can be experienced with therapeutic proteins.

 

Dr. Stefano Pluchino, Chief Scientific Officer of ReNeuron, commented: "I am delighted to see these extremely compelling data showing that exosomes efficiently deliver therapeutic proteins to targeted brain regions associated with severe neurological diseases. These data are the foundation of one of the main corporate programmes at ReNeuron and highlight the possibility to deliver other payloads using the same principles and technology platform, providing improved tissue distribution and specificity. This exciting strategy could potentially be used to deliver single therapies or multiple therapeutics with exosomes, enabling a number of exciting next generation precision medicine approaches."

 

Olav Hellebø, CEO, commented: "These results are a key milestone for our exosome delivery technology, establishing clear proof of concept in vivo, which more accurately imitates conditions for the targeted delivery of key neurological therapeutics into the human brain. In 2020 we refocussed the business on our exosome platform, as well as our retinal disease programme and iPSC platform, and these results show just how significant the potential is for exosomes to become a novel means of delivering third party biological drugs to the brain and other regions of the body. This is exciting news for the major pharmaceutical and biotechnology partners that we have collaboration agreements with and underpins the commercial opportunity that our platform provides."

 

 

ENDS

 

Contacts:

 

ReNeuron

www.reneuron.com/investors

Olav Hellebø, Chief Executive Officer

Via Walbrook PR

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

+44 (0)20 7710 7600

Ben Maddison, Stewart Wallace

Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)

Stefano Aquilino (Sales & Corporate Broking)

Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBLBDGDUGDGBI
Date   Source Headline
9th Jan 20127:00 amRNSNotification of Stem Cell Technical Seminar
3rd Jan 20127:00 amRNSData confirms pre-clinical efficacy of ReN001
19th Dec 20114:41 pmRNSSecond Price Monitoring Extn
19th Dec 20114:35 pmRNSPrice Monitoring Extension
6th Dec 201110:00 amRNSWelcomes UK Government Life Sciences Strategy
30th Nov 20114:35 pmRNSPrice Monitoring Extension
28th Nov 20117:00 amRNSStroke Update
28th Nov 20117:00 amRNSInterim Results
9th Nov 20117:00 amRNSStroke clinical trial update & notice of results
3rd Nov 20112:54 pmRNSNotification of Major Interest in Shares
1st Nov 20112:13 pmRNSNotification of Interest in Shares
31st Oct 201110:42 amRNSNotification of Major Interest in Shares
22nd Sep 201112:53 pmRNSDirectors' Interest in Shares and Share Options
22nd Sep 201112:48 pmRNSDirectors' Interest in Shares
15th Sep 201110:45 amRNSResults of 2011 Annual General Meeting
15th Sep 20117:00 amRNSAGM Trading Update
1st Sep 20114:35 pmRNSPrice Monitoring Extension
1st Sep 20117:00 amRNSReNeuron receives DSMB clearance
29th Jul 20113:24 pmRNSAnnual Report and Accounts and Notice of AGM
20th Jul 20117:00 amRNSBoard Appointments
5th Jul 20117:00 amRNSContract with Angel Biotechnology Holdings plc
5th Jul 20117:00 amRNSAngel signs new contract with ReNeuron
30th Jun 20117:00 amRNSPreliminary Results
24th Jun 20112:56 pmRNSReNeuron launches new website
16th Jun 20117:00 amRNSLicense agreement with US eye research institute
1st Jun 20119:43 amRNSBlock Listing Six Monthly Review
27th May 20117:00 amRNSNotice of Results and Stroke Clinical Trial Update
28th Apr 201112:22 pmRNSEU legal opinion
8th Apr 20117:00 amRNSManufacturing Agreement
28th Jan 20117:00 amRNSSettlement with Neuralstem, Inc
10th Jan 20112:18 pmRNSTR-1 Notification of major interest in shares
10th Jan 20117:00 amRNSTR-1 Notification of major interest in shares
7th Jan 20117:00 amRNSTR-1: Notification of major interest in shares
4th Jan 20117:00 amRNSMajor Interest in Shares
29th Dec 201011:34 amRNSRESULT OF GENERAL MEETING & THIRD ADMISSION
21st Dec 20107:00 amRNSUpdate on clinical trial
20th Dec 20108:01 amRNSSECOND ADMISSION
17th Dec 20108:01 amRNSFIRST ADMISSION
13th Dec 20107:01 amRNSInterim Results
13th Dec 20107:00 amRNS£10 million Fundraising
1st Dec 20107:00 amRNSBlock Listing Six Monthly Review
17th Nov 20104:41 pmRNSSecond Price Monitoring Extn
17th Nov 20104:35 pmRNSPrice Monitoring Extension
17th Nov 20107:00 amRNSProgress update on ReN009
16th Nov 20107:00 amRNSFirst Patient Treated with ReN001
27th Oct 20107:00 amRNSReNeuron at stem cell and neuroscience conferences
8th Oct 201010:26 amRNS18th Annual BioPartnering Europe conference
8th Sep 201011:07 amRNSResults of 2010 Annual General Meeting
8th Sep 20107:00 amRNS2010 AGM Trading Update
9th Aug 20107:00 amRNSPosting of Report and Accounts and AGM date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.